As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had spread to almost every country in the world, and more than 6.86 million people had died after contracting the respiratory virus. Over 1.16 million of these deaths occurred in the United States.

Waves of infections Almost every country and territory worldwide have been affected by the COVID-19 disease. At the end of 2021 the virus was once again circulating at very high rates, even in countries with relatively high vaccination rates such as the United States and Germany. As rates of new infections increased, some countries in Europe, like Germany and Austria, tightened restrictions once again, specifically targeting those who were not yet vaccinated. However, by spring 2022, rates of new infections had decreased in many countries and restrictions were once again lifted.

What are the symptoms of the virus? It can take up to 14 days for symptoms of the illness to start being noticed. The most commonly reported symptoms are a fever and a dry cough, leading to shortness of breath. The early symptoms are similar to other common viruses such as the common cold and flu. These illnesses spread more during cold months, but there is no conclusive evidence to suggest that temperature impacts the spread of the SARS-CoV-2 virus. Medical advice should be sought if you are experiencing any of these symptoms.

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

As of 2023, the countries with the highest death rates worldwide were Monaco, Bulgaria, and Latvia. In these countries, there were ** to ** deaths per 1,000 people. The country with the lowest death rate is Qatar, where there is just *** death per 1,000 people. Leading causes of death The leading causes of death worldwide are, by far, cardiovascular diseases, accounting for ** percent of all deaths in 2021. That year, there were **** million deaths worldwide from ischaemic heart disease and **** million from stroke. Interestingly, a worldwide survey from that year found that people greatly underestimate the proportion of deaths caused by cardiovascular disease, but overestimate the proportion of deaths caused by suicide, interpersonal violence, and substance use disorders. Death in the United States In 2023, there were around **** million deaths in the United States. The leading causes of death in the United States are currently heart disease and cancer, accounting for a combined ** percent of all deaths in 2023. Lung and bronchus cancer is the deadliest form of cancer worldwide, as well as in the United States. In the U.S. this form of cancer is predicted to cause around ****** deaths among men alone in the year 2025. Prostate cancer is the second-deadliest cancer for men in the U.S. while breast cancer is the second deadliest for women. In 2023, the tenth leading cause of death in the United States was COVID-19. Deaths due to COVID-19 resulted in a significant rise in the total number of deaths in the U.S. in 2020 and 2021 compared to 2019, and it was the third leading cause of death in the U.S. during those years.

Introduction: Prognosis of Coronavirus disease 2019 (Covid-19) patients with vascular risk factors, and certain comorbidities is worse. The impact of chronic neurological disorders (CND) on prognosis is unclear. We evaluated if the presence of CND in Covid-19 patients is a predictor of a higher in-hospital mortality. As secondary endpoints, we analyzed the association between CND, Covid-19 severity, and laboratory abnormalities during admission.Methods: Retrospective cohort study that included all the consecutive hospitalized patients with confirmed Covid-19 disease from March 8th to April 11th, 2020. The study setting was Hospital Clínico, tertiary academic hospital from Valladolid. CND was defined as those neurological conditions causing permanent disability. We assessed demography, clinical variables, Covid-19 severity, laboratory parameters and outcome. The primary endpoint was in-hospital all-cause mortality, evaluated by multivariate cox-regression log rank test. We analyzed the association between CND, covid-19 severity and laboratory abnormalities.Results: We included 576 patients, 43.3% female, aged 67.2 years in mean. CND were present in 105 (18.3%) patients. Patients with CND were older, more disabled, had more vascular risk factors and comorbidities and fewer clinical symptoms of Covid-19. They presented 1.43 days earlier to the emergency department. Need of ventilation support was similar. Presence of CND was an independent predictor of death (HR 2.129, 95% CI: 1.382–3.280) but not a severer Covid-19 disease (OR: 1.75, 95% CI: 0.970–3.158). Frequency of laboratory abnormalities was similar, except for procalcitonin and INR.Conclusions: The presence of CND is an independent predictor of mortality in hospitalized Covid-19 patients. That was not explained neither by a worse immune response to Covid-19 nor by differences in the level of care received by patients with CND.

IntroductionCoronavirus disease 2019 (COVID-19) has caused more than 690 million deaths worldwide. Different results concerning the death rates of the Delta and Omicron variants have been recorded. We aimed to assess the secular trend of case fatality rate (CFR), identify risk factors associated with mortality following COVID-19 diagnosis, and investigate the risks of mortality and hospitalization during Delta and Omicron waves in the United States.MethodsThis study assessed 2,857,925 individuals diagnosed with COVID-19 in the United States from January 2020, to June 2022. The inclusion criterion was the presence of COVID-19 diagnostic codes in electronic medical record or a positive laboratory test of the SARS-CoV-2. Statistical analysis was bifurcated into two components, longitudinal analysis and comparative analysis. To assess the discrepancies in hospitalization and mortality rates for COVID-19, we identified the prevailing periods for the Delta and Omicron variants.ResultsLongitudinal analysis demonstrated four sharp surges in the number of deaths and CFR. The CFR was persistently higher in males and older age. The CFR of Black and White remained higher than Asians since January 2022. In comparative analysis, the adjusted hazard ratios for all-cause mortality and hospitalization were higher in Delta wave compared to the Omicron wave. Risk of all-cause mortality was found to be greater 14–30 days after a COVID-19 diagnosis, while the likelihood of hospitalization was higher in the first 14 days following a COVID-19 diagnosis in Delta wave compared with Omicron wave. Kaplan–Meier analysis revealed the cumulative probability of mortality was approximately 2-fold on day 30 in Delta than in Omicron cases (log-rank p 

In 2022, the most common cause of death in Sweden was diseases of the circulatory system. More than 28,000 people died because of these diseases. Cancer was the second most common cause of death in Sweden. Furthermore, diseases of the respiratory system caused over 6,000 deaths in Sweden in 2022.

Ischemic heart disease most common cause

Chronic ischemic heart disease is the circulation system disease that causes the most number of deaths. When ischemic heart disease occurs, the arteries of the heart are blocked and the blood flow to the heart muscle is reduced. Heart attacks caused the second most deaths of the circulatory system diseases.

 COVID-19

From 2019 to 2020, the total number of deaths in Sweden increased by around 10,000, almost reaching 100,000 in total. This can be explained by the more than 9,400 deaths caused by the coronavirus (COVID-19). At the beginning of the pandemic, the Swedish government tried a different approach than most other European countries, avoiding strict lockdowns and regulations. However, it has recorded a higher number of deaths and cases than the other Nordic countries. As of January 2023, nearly 23,000 people had died of COVID-19 in Sweden.

Peru is the country with the highest mortality rate due to the coronavirus disease (COVID-19) in Latin America. As of November 13, 2023, the country registered over 672 deaths per 100,000 inhabitants. It was followed by Brazil, with around 331.5 fatal cases per 100,000 population. In total, over 1.76 million people have died due to COVID-19 in Latin America and the Caribbean.

Are these figures accurate? Although countries like Brazil already rank among the countries most affected by the coronavirus disease (COVID-19), there is still room to believe that the number of cases and deaths in Latin American countries are underreported. The main reason is the relatively low number of tests performed in the region. For example, Brazil, one of the most impacted countries in the world, has performed approximately 63.7 million tests as of December 22, 2022. This compared with over one billion tests performed in the United States, approximately 909 million tests completed in India, or around 522 million tests carried out in the United Kingdom.

Capacity to deal with the outbreak With the spread of the Omicron variant, the COVID-19 pandemic is putting health systems around the world under serious pressure. The lack of equipment to treat acute cases, for instance, is one of the problems affecting Latin American countries. In 2019, the number of ventilators in hospitals in the most affected countries ranged from 25.23 per 100,000 inhabitants in Brazil to 5.12 per 100,000 people in Peru.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of March 10, 2023, there have been 1.1 million deaths related to COVID-19 in the United States. There have been 101,159 deaths in the state of California, more than any other state in the country – California is also the state with the highest number of COVID-19 cases.

The vaccine rollout in the U.S. Since the start of the pandemic, the world has eagerly awaited the arrival of a safe and effective COVID-19 vaccine. In the United States, the immunization campaign started in mid-December 2020 following the approval of a vaccine jointly developed by Pfizer and BioNTech. As of March 22, 2023, the number of COVID-19 vaccine doses administered in the U.S. had reached roughly 673 million. The states with the highest number of vaccines administered are California, Texas, and New York.

Vaccines achieved due to work of research groups Chinese authorities initially shared the genetic sequence to the novel coronavirus in January 2020, allowing research groups to start studying how it invades human cells. The surface of the virus is covered with spike proteins, which enable it to bind to human cells. Once attached, the virus can enter the cells and start to make people ill. These spikes were of particular interest to vaccine manufacturers because they hold the key to preventing viral entry.

India recorded 531794 Coronavirus Deaths since the epidemic began, according to the World Health Organization (WHO). In addition, India reported 44983152 Coronavirus Cases. This dataset includes a chart with historical data for India Coronavirus Deaths.

Dose-Counting Smart Inhaler Label Market Outlook

According to our latest research, the global dose-counting smart inhaler label market size reached USD 1.14 billion in 2024, with a robust year-over-year growth trajectory. The market is expected to expand at a CAGR of 11.2% from 2025 to 2033, ultimately reaching an estimated USD 3.02 billion by 2033. This sustained growth is primarily driven by the increasing prevalence of chronic respiratory diseases, technological advancements in inhaler devices, and the rising demand for patient-centric healthcare solutions. The integration of digital health technologies and the growing emphasis on medication adherence are further fueling the adoption of dose-counting smart inhaler labels worldwide.

One of the most significant growth factors propelling the dose-counting smart inhaler label market is the mounting global burden of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization, over 262 million people were affected by asthma globally in 2023, with COPD ranking as the third leading cause of death worldwide. This alarming prevalence has led to a surge in demand for advanced inhalation therapies that not only deliver medication efficiently but also ensure accurate dose tracking. Dose-counting smart inhaler labels address this critical need by providing real-time feedback on medication usage, thereby minimizing the risk of under- or over-dosing and enhancing patient safety. As healthcare systems increasingly focus on preventive care and chronic disease management, the adoption of smart inhaler technologies is expected to accelerate further.

Another pivotal growth driver is the rapid advancement in digital health technologies, particularly the integration of Internet of Things (IoT), Bluetooth, and sensor-based solutions into inhaler devices. These innovations have transformed traditional inhalers into smart, connected devices capable of transmitting usage data to healthcare providers and patients in real time. The proliferation of mobile health (mHealth) applications and cloud-based platforms has further simplified the monitoring and management of respiratory conditions, enabling personalized treatment regimens and improved medication adherence. Moreover, the growing trend towards remote patient monitoring and telemedicine, especially in the wake of the COVID-19 pandemic, has underscored the importance of dose-counting smart inhaler labels in supporting virtual healthcare delivery models.

Additionally, the market is benefiting from favorable regulatory policies, increased investments in healthcare infrastructure, and rising awareness about the benefits of smart inhaler technologies among patients and healthcare professionals. Governments and non-profit organizations across the globe are launching initiatives to promote respiratory health and reduce the economic burden of chronic diseases. Pharmaceutical companies and medical device manufacturers are also collaborating to develop innovative, patient-friendly inhaler solutions that comply with stringent quality and safety standards. These collaborative efforts are expected to create new growth opportunities for the dose-counting smart inhaler label market over the forecast period, particularly in emerging economies with rapidly expanding healthcare sectors.

From a regional perspective, North America currently dominates the global dose-counting smart inhaler label market, accounting for the largest revenue share in 2024. This leadership position is attributed to the high prevalence of respiratory diseases, advanced healthcare infrastructure, and strong presence of leading market players in the region. Europe follows closely, driven by increasing healthcare expenditure and supportive government initiatives. The Asia Pacific region, on the other hand, is poised for the fastest growth during the forecast period, owing to its large patient population, rising disposable incomes, and growing awareness about smart healthcare solutions. Latin America and the Middle East & Africa are also witnessing steady growth, albeit at a comparatively slower pace, as healthcare systems in these regions continue to evolve and modernize.

COVID-19 rate of death, or the known deaths divided by confirmed cases, was over ten percent in Yemen, the only country that has 1,000 or more cases. This according to a calculation that combines coronavirus stats on both deaths and registered cases for 221 different countries. Note that death rates are not the same as the chance of dying from an infection or the number of deaths based on an at-risk population. By April 26, 2022, the virus had infected over 510.2 million people worldwide, and led to a loss of 6.2 million. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. Note that Statista aims to also provide domestic source material for a more complete picture, and not to just look at one particular source. Examples are these statistics on the confirmed coronavirus cases in Russia or the COVID-19 cases in Italy, both of which are from domestic sources. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

A word on the flaws of numbers like this

People are right to ask whether these numbers are at all representative or not for several reasons. First, countries worldwide decide differently on who gets tested for the virus, meaning that comparing case numbers or death rates could to some extent be misleading. Germany, for example, started testing relatively early once the country’s first case was confirmed in Bavaria in January 2020, whereas Italy tests for the coronavirus postmortem. Second, not all people go to see (or can see, due to testing capacity) a doctor when they have mild symptoms. Countries like Norway and the Netherlands, for example, recommend people with non-severe symptoms to just stay at home. This means not all cases are known all the time, which could significantly alter the death rate as it is presented here. Third and finally, numbers like this change very frequently depending on how the pandemic spreads or the national healthcare capacity. It is therefore recommended to look at other (freely accessible) content that dives more into specifics, such as the coronavirus testing capacity in India or the number of hospital beds in the UK. Only with additional pieces of information can you get the full picture, something that this statistic in its current state simply cannot provide.

The Sepsis Diagnosis market was valued at USD 1.20 Billion in 2022 and will reach USD 2.5 Billion by 2030, registering a CAGR of 9.9% for the forecast period 2023-2030.

Increasing prevalence of sepsis Sepsis is a life-threatening condition caused by a severe infection. The global prevalence of sepsis has been rising, creating a significant demand for effective diagnostics tools. The growing awareness about sepsis and its early detection has led to an increased emphasis on sepsis diagnostics. Around 30% of COVID-19 patients in Seattle, United States, displayed signs of liver damage in April 2020, and about 75% reported having a suppressed immune response, Which was reported according to Global Sepsis Alliance. They also revealed that among the non-survivors around 50% of patients had a secondary infection, almost 100% of the non-survivours had sepsis and about 70% had septic shock.

Technological advancements The development of innovative diagnostic technologies has significantly improved the accuracy and speed of sepsis detection. Advanced molecular diagnostic techniques, biomarkers, and automated systems have enabled early and accurate diagnosis of sepsis, leading to better patient management. The newly developed test uses microelectrode to analyze the patient's blood and can provide final results in around two and a half minutes. Thus technological advancements continue to drive the growth of the sepsis diagnostics market.

Restraining Factors Cost Constraints Sepsis diagnostics tests, especially advanced molecular and genomic techniques, can be expensive. High costs associated with these tests may pose a challenge for their widespread adoption, particularly in resource-limited settings or regions with inadequate healthcare budgets. The cost of sepsis management in U.S. hospitals ranks highest among admissions for all disease states. For example, in 2013, sepsis accounted for more than $24 billion in hospitals, the second most costly being osteoarthritis at $17 billion and the third most costly being childbirth at $13 billion. The timing of sepsis diagnosis is critical in terms of outcomes given the acute and significant impact of the condition., Poor sepsis outcomes are observed when diagnosis and treatment are delayed resulting in the loss of money. Thus the cost is one of the main restraining factors in sepsis diagnosis.

Regulatory and Reimbursement Issues The regulatory approval process for new sepsis diagnostic tests can be lengthy and complex. Additionally, reimbursement policies and coverage for sepsis diagnostics may vary among different healthcare systems and regions. These factors can impact the market dynamics and hinder the adoption of new diagnostic technologies. Impact of the COVID-19 Pandemic on the Sepsis Diagnostic Market: COVID-19 has negatively impacted the market. The management of sickness and medication adherence is made more difficult by lockdowns and isolation during pandemics. The industry will also be impacted by the lack of accessibility to medical facilities for standard care and pharmaceutical administration. Stress, hopelessness, and unsupportive results in social isolation, there may be a decrease in sepsis treatment adherence throughout the pandemic which has affected the overall market. According to the Global Sepsis Alliance, around 30% of COVID-19 patients have evidence of liver injury and around 75% reported a depressed immune response. Moreover, COVID-19 patients pose a higher risk of developing coinfections. The study revealed that among the non-survivors, around 50% of patients had a secondary infection, almost 100% of the non-survivors had sepsis, and about 70% had septic shock.

Sepsis is an unsafe condition that can emerge from harmful microbes in the blood or other tissues; the body's reaction to their presence may cause shock or even death. The leading cause of sepsis is bacterial infection and other infections. Factors such as the high prevalence of sepsis, increasing awareness, and introduction of technologically advanced diagnostic solutions are expected to significantly fuel the market growth over the forecast period. According to the data published by the WHO in April 2018, globally, this condition affects more than 30 million people and leads to around 6 million deaths every year. Such a high prevalence is anticipated to increase demand for its diagnostic solutions.

In Los Angeles County, methamphetamine accounted for the highest share of overdose deaths among people experiencing homelessness (PEH) in the 12 months before and after the COVID-19 pandemic onset, contributing to approximately three-quarters of all overdose deaths in both years. Fentanyl ranked as the second leading cause of overdose death in both periods, but showed the largest increase in its contribution over the analyzed timeframe. This statistic depicts the percentage of deaths among people experiencing homelessness by overdose pre- and post-COVID-19 pandemic in Los Angeles County, by drug type.

In 2023, the leading causes of death in Canada were malignant neoplasms (cancer) and diseases of the heart. Together, these diseases accounted for around ** percent of all deaths in Canada that year. COVID-19 was the sixth leading cause of death in Canada in 2023 with *** percent of deaths. The leading causes of death in Canada In 2023, around ****** people in Canada died from cancer, making it by far the leading cause of death in the country. In comparison, an estimated ****** people died from diseases of the heart, while ****** died from accidents. In 2023, the death rate for diabetes mellitus was **** per 100,000 population, making it the seventh leading cause of death. Diabetes is a growing problem in Canada, with around ***** percent of the population diagnosed with the disease as of 2023. What is the deadliest form of cancer in Canada? In Canada, lung and bronchus cancer account for the largest share of cancer deaths, followed by colorectal cancer. In 2023, the death rate for lung and bronchus cancer was **** per 100,000 population, compared to **** deaths per 100,000 population for colorectal cancer. However, although lung and bronchus cancer are the deadliest cancers for both men and women in Canada, breast cancer is the second-deadliest cancer among women, accounting for **** percent of all cancer deaths. Colorectal cancer is the second most deadly cancer among men in Canada, followed by prostate cancer. In 2023, colorectal cancer accounted for around **** percent of all cancer deaths among men in Canada, while prostate cancer was responsible for **** percent of such deaths.

As of August 2, 2023, Mexico was the third Latin American country with the highest number of confirmed cases of COVID-19, reaching over 7.6 million patients. By federate entity, Mexico City ranked first in number of confirmed cases, with around 1.9 million infections recorded by September 21, 2023. The State of Mexico followed with 760,699 reported cases of the disease.

The leading cause of death in Mexico in 2020
In 2020, COVID-19 was the leading cause of death in Mexico. The country reported its first fatal case due to the disease in March 2020. Since then, the number of COVID-19 deaths has increased steadily, reaching 334,336 deaths as of August 2, 2023. These figures place Mexico fifth in the total number of deaths related to COVID worldwide and second in Latin America, just after Brazil.

Mexico’s vaccination strategy Mexico began its vaccination campaign at the end of December 2020, an immunization strategy that prioritized healthcare workers and those most at risk of developing severe COVID-19, such as the older population. With more than 223 million vaccines administered as of August 14, 2023, Mexico ranked as the Latin American country with the second highest number of applied vaccines, while slightly over three quarters of its population received at least one vaccine dose against the disease by March 2023.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Heart conditions were the most common causes of death in Mexico in 2023. During that period, more than ******* people died in the North American country as a result from said conditions. Diabetes mellitus ranked second, with over ******* deaths registered that year. Obesity in MexicoObesity and being overweight can worsen many risk factors for developing heart conditions, prediabetes, type 2 diabetes, and gestational diabetes, which in the case of a COVID-19 infection can lead to a severe course of the disease. In 2020, Mexico was reported as having one of the largest overweight and/or obese population in Latin America, with ** percent of people in the country having a body mass index higher than 25. In 2022, obesity was announced as being one of the most common illnesses experienced in Mexico, with over ******* cases estimated. In a decade from now, it is predicted that about *** million children in Mexico will suffer from obesity. If estimations are correct, this North American country will belong to the world’s top 10 countries with the most obese children in 2030. Physical activity in MexicoIt is not only a matter of food intake. A 2023 survey found, for instance, that only **** percent of Mexican population practiced sports and physical activities in their free time, a figure that has decreased in comparison to 2013. Less than ** percent of the physically active Mexicans practice sports for fun. However, the vast majority were motivated by health reasons.

As of March 10, 2023, the state with the highest rate of COVID-19 cases was Rhode Island followed by Alaska. Around 103.9 million cases have been reported across the United States, with the states of California, Texas, and Florida reporting the highest numbers of infections.

From an epidemic to a pandemic The World Health Organization declared the COVID-19 outbreak as a pandemic on March 11, 2020. The term pandemic refers to multiple outbreaks of an infectious illness threatening multiple parts of the world at the same time; when the transmission is this widespread, it can no longer be traced back to the country where it originated. The number of COVID-19 cases worldwide is roughly 683 million, and it has affected almost every country in the world.

The symptoms and those who are most at risk Most people who contract the virus will suffer only mild symptoms, such as a cough, a cold, or a high temperature. However, in more severe cases, the infection can cause breathing difficulties and even pneumonia. Those at higher risk include older persons and people with pre-existing medical conditions, including diabetes, heart disease, and lung disease. Those aged 85 years and older have accounted for around 27 percent of all COVID deaths in the United States, although this age group makes up just two percent of the total population

As of 2023, the third leading cause of death among teenagers aged 15 to 19 years in the United States was intentional self-harm or suicide, contributing to around 17 percent of deaths among this age group. The leading cause of death at that time was unintentional injuries, contributing to around 38.6 percent of deaths, while 20.7 percent of all deaths in this age group were due to assault or homicide. Cancer and heart disease, the overall leading causes of death in the United States, are also among the leading causes of death among U.S. teenagers. Adolescent suicide in the United States In 2021, around 22 percent of students in grades 9 to 12 reported that they had seriously considered attempting suicide in the past year. Female students were around twice as likely to report seriously considering suicide compared to male students. In 2023, New Mexico had the highest rate of suicides among U.S. teenagers, with around 28 deaths per 100,000 teenagers, followed by Idaho with a rate of 22.5 per 100,000. The states with the lowest death rates among adolescents are New Jersey and New York. Mental health treatment Suicidal thoughts are a clear symptom of mental health issues. Mental health issues are not rare among children and adolescents, and treatment for such issues has become increasingly accepted and accessible. In 2021, around 15 percent of boys and girls aged 5 to 17 years had received some form of mental health treatment in the past year. At that time, around 35 percent of youths aged 12 to 17 years in the United States who were receiving specialty mental health services were doing so because they had thought about killing themselves or had already tried to kill themselves.

In 2021, the leading causes of death worldwide were ischemic heart disease, COVID-19, and stroke. That year, ischemic heart disease caused over nine million deaths, while COVID-19 resulted in 8.7 million deaths. In 2019, just before the COVID-19 pandemic, the leading causes of death worldwide were ischemic heart disease, stroke, and chronic obstructive pulmonary disease (COPD).